The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Vedolizumab and Ustekinumab Algorithm in Ulcerative Colitis

Selection and sequencing strategies among advanced biologic therapies.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Dahiliye (İç Hastalıkları) department. Book Appointment →

What is Vedolizumab and Ustekinumab Algorithm in Ulcerative Colitis?

In moderate-to-severe active ulcerative colitis (UC), vedolizumab (anti-integrin) and ustekinumab (anti-IL-12/23) are effective alternatives in patients who are unresponsive to or have lost response to anti-TNF agents.

Vedolizumab maintains a low infection risk due to its gut-selective effect, making it preferable in elderly and comorbid patients. Ustekinumab is advantageous in systemic disease involvement or overlapping conditions like psoriatic arthritis.

Treatment selection is individualized based on disease severity, extraintestinal involvement, infection risk, prior biologic history, and patient preference. Therapeutic drug monitoring is increasingly used.

Symptoms

Frequent bloody diarrhea
Urgency and tenesmus
Abdominal pain
Fatigue and weight loss
Anemia
Extraintestinal arthritis
Skin lesions (pyoderma, erythema nodosum)

Risk Factors

Anti-TNF primary nonresponse
Secondary loss of response
High infection risk
Coexisting psoriatic arthritis
Elderly patient profile
Recurrent hospitalizations
Complicated fistula/stricture

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Active UC unresponsive to conventional therapy
  • Anti-TNF failure
  • Development of infusion reaction
  • Colectomy evaluation
  • Decision for biologic switching
  • Pregnancy planning

Treatment Methods

01
Vedolizumab induction and maintenance schedule
02
Ustekinumab IV initiation + SC maintenance
03
Therapeutic drug monitoring
04
Corticosteroid tapering plan
05
Selection based on patient risk profile
06
Ustekinumab priority in psoriatic arthritis
07
Vedolizumab safety preference in elderly
08
Gastroenterology follow-up

Which Department to Visit?

You can visit our Dahiliye (İç Hastalıkları) department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Dahiliye (İç Hastalıkları) Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Anaemia

Dahiliye (İç Hastalıkları)

Anaemia is a low haemoglobin level that reduces oxygen delivery, causing fatigue, pallor, and shortness of breath. It is not a disease itself but a sign of many underlying conditions. Most cases are correctable with appropriate diagnosis and treatment.

Iron Deficiency Anaemia

Dahiliye (İç Hastalıkları)

Iron deficiency anaemia develops when dietary intake, absorption, or losses create an iron shortfall, most often affecting women and children. Identifying the underlying cause is the core of management, alongside iron replacement.

Vitamin B12 Deficiency

Dahiliye (İç Hastalıkları)

Vitamin B12 deficiency can cause megaloblastic anaemia, neurological symptoms, and cognitive impairment. Early treatment with intramuscular or oral B12 largely prevents irreversible complications.

Hypertension (High Blood Pressure) Management

Dahiliye (İç Hastalıkları)

Hypertension is often called the silent killer because it progresses symptom-free for years and can damage the heart, brain, kidneys, and eyes. Regular monitoring, lifestyle change, and evidence-based drug therapy dramatically reduce cardiovascular risk.

Chronic Kidney Disease

Dahiliye (İç Hastalıkları)

Chronic kidney disease is one of the most common complications of chronic conditions such as diabetes and hypertension, and can be silent in its early stages.

Hepatitis B (HBV)

Dahiliye (İç Hastalıkları)

Hepatitis B is a DNA virus infection causing acute and chronic hepatitis with risk of cirrhosis and hepatocellular carcinoma; diagnosis integrates HBsAg, HBeAg, anti-HBc, and HBV DNA with management based on disease phase using nucleos(t)ide analogues (entecavir, tenofovir) and universal infant vaccination.

Hepatitis C (HCV)

Dahiliye (İç Hastalıkları)

Hepatitis C is an RNA virus causing chronic hepatitis that may progress to cirrhosis and hepatocellular carcinoma; modern direct-acting antiviral (DAA) pangenotypic regimens (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir) achieve sustained virologic response over 95% in 8–12 weeks with universal adult screening and cure for nearly all patients.

Fatty Liver Disease

Dahiliye (İç Hastalıkları)

Non-alcoholic fatty liver disease (NAFLD) is closely related to obesity and metabolic syndrome and is largely reversible with early treatment.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.